EBV Active p23 (DAG-P2787)

EBV Active p23 (aa 1 - 162), recombinant protein from E. coli

Product Overview
Active EBV p23 full length protein
Nature
Recombinant
Tag/Conjugate
Unconjugated
Cellular Localization
virion
Bio-activity
This protein is immunoreactive with sera of EBV-infected individuals.
Procedure
None
Purity
> 95 % by SDS-PAGE.This protein was purified by proprietary chromatographic techniques.
Format
Liquid
Buffer
Preservative: None Constituents: 50% Glycerol, 25mM Glycine, pH 9.6
Preservative
None
Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. Preservative: None Constituents: 50% Glycerol, 25mM Glycine, pH 9.6 This product is an active protein and may elicit a biological response in vivo, handle with caution.
Introduction
The Epstein–Barr virus (EBV), also called human herpesvirus 4 (HHV-4), is a virus of the herpes family, and is one of the most common viruses in humans.
Antigen Description
p23 is one of the two small viral capsid antigens (VCA). EBV p23 is a viral late complex associated with virion particles and consists of two gene products, BFRF3 and BLRF2. EBV has a worldwide distribution, with over 90% of the adult population showing evidence of past infection. The virus, acquired during childhood, usually causes no symptoms. However, in Western societies, 10 to 20% of adolescents and young adults develop acute infectious mononucleosis (IM). In humans, EBV is also associated with cancer, in particular Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's disease, and immunoblastic lymphoma.
Keywords
EBV; Epstein Barr virus p23 protein; HHV4 p23; Human Herpesvirus 4; Probable capsid protein VP23; Protein BDLF1; VP23; EBV p23

Citations


Have you cited DAG-P2787 in a publication? Let us know and earn a reward for your research.

Related Products


EBV P23 [GST] (DAG511)
EBV P23 (DAG3928)

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Efficient evaluation of humoral immune responses by the use of serum pools

JOURNAL OF IMMUNOLOGICAL METHODS

Authors: Sternbaek, Louise; Draborg, Anette H.; Nielsen, Christoffer T.; Jacobsen, Soren; Iversen, Line V.; Troelsen, Lone; Theander, Elke; Houen, Gunnar

Background: Collection and testing of individual serum samples are often used in research to gain knowledge about e.g. the humoral response against bacteria or virus. This is a valid but time-consuming method and might be a waste of valuable serum samples for inefficient research. So far, no study has considered using serum pools as a quick and efficient screening method to confirm or deny hypotheses. Methods: We created serum pools from four different patient groups (systemic lupus erythematosus n = 85, rheumatoid arthritis n = 77, Sjogren's syndrome n = 91, systemic sclerosis n = 66) and one healthy control group (n = 67). Each serum pool was analyzed using three well-known immunoassays: enzyme-linked immunosorbent assay (ELISA), line blot, and immunofluorescence microscopy (anti-nuclear antibody (ANA) screening). The presence of Epstein -Barr virus (EBV) EA/D-, EBNA-1-, VCA p23-, and gp350-directed antibodies was used to validate serum pools as an efficient tool for further investigations by comparison to previous findings in this area. Results: The presence of EBV EA/D-, EBNA-1-, VCA p23-, and gp350-directed antibodies in each pool was consistent within the obtained ELISA and line blot results, as increased titers of IgG against the four antigens were found in all patient serum pools and also in individual sera regarding gp350. These results correspond to previous findings on individual samples from patients with these diseases. The presence of ANAs was observed in all four patient serum pools and not in the HC pool by both line blots and immunofluorescence microscopy, which corresponds with the expectations and further corroborate the application of serum pools for screenings. Conclusion: We developed and validated the use of serum pools that reliably and rapidly can confirm or deny hypotheses, which enables a more efficient research concentrating on the most evident factors. (C) 2017 Elsevier B.V. All rights reserved.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket